Security
X4 Pharmaceuticals Inc Warrants Expiring 04/12/2024 · XFORW
XFORWOTCWarrantHistorical · closed Apr 9, 2024CIK 1501697Updated Oct 3, 2026
Name history
Arsanis, Inc. · through Mar 13, 2019
Current security for this SEC filerXFOR · NASDAQ
XFORW price & chart
Historical security
This listing closed Apr 9, 2024. Live provider charts are shown only for current listings.
Current security: XFOR
About the company
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain
In the news
No coverage from other publishers is available.
Recent filings
144 filing
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
SCHEDULE 13G/A - filed by Deep Track Capital, LP regarding X4 Pharmaceuticals, Inc
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 290,461,000Source | 146,447,000Source | 147,258,000Source | 155,586,000Source |
| Property, Plant and Equipment, NetUSD | 182,000Source | 776,000Source | 745,000Source | 1,104,000Source |
| GoodwillUSD | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 217,049,000Source | 55,699,000Source | 99,216,000Source | 121,718,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 573,000Source | 1,070,000Source | — | — |
| Inventory, NetUSD | — | 2,817,000Source | — | — |
| Assets, CurrentUSD | 261,577,000Source | 112,175,000Source | 122,076,000Source | 128,677,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,527,000Source | 5,588,000Source | 7,298,000Source | 5,807,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,409,000Source | 4,065,000Source | 5,650,000Source | 7,229,000Source |
| Other Assets, NoncurrentUSD | 692,000Source | 2,080,000Source | 1,436,000Source | 1,225,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 104,171,000Source | 124,298,000Source | 96,159,000Source | 81,535,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 91,000Source | 171,000Source | 167,000Source | 122,000Source |
| Retained Earnings (Accumulated Deficit)USD | -594,554,000Source | -515,355,000Source | -477,905,000Source | -376,738,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -109,000Source | -122,000Source | -119,000Source | -119,000Source |
| Stockholders' Equity Attributable to ParentUSD | 186,290,000Source | 22,149,000Source | 51,099,000Source | 74,051,000Source |
| Additional Paid in Capital, Common StockUSD | 780,862,000Source | 537,455,000Source | 528,956,000Source | 450,786,000Source |
| Liabilities and EquityUSD | 290,461,000Source | 146,447,000Source | 147,258,000Source | 155,586,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 25,757,000Source | 32,877,000Source | 22,862,000Source | 22,324,000Source |
| Operating Lease, Liability, CurrentUSD | 994,000Source | 1,251,000Source | 1,099,000Source | 1,198,000Source |
| Accounts Payable, CurrentUSD | 5,696,000Source | 8,621,000Source | 8,947,000Source | 7,777,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 1,410,000Source | 2,612,000Source | 3,603,000Source |
| Other Liabilities, NoncurrentUSD | 525,000Source | 831,000Source | 432,000Source | 173,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 18,603,000Source | 23,005,000Source | 12,816,000Source | 12,034,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 253,000,000Source | 102,100,000Source | 114,200,000Source | — |
| Long-term DebtUSD | 75,000,000Source | 75,000,000Source | — | — |
| Long-term Debt, Current MaturitiesUSD | — | — | 0Source | 1,315,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 54,570,000Source | 32,304,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | -37,450,000Source | -101,167,000Source | -93,867,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,277,000Source | 796,000Source | 419,000Source | 513,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 4,298,000Source | 8,204,000Source | 8,687,000Source | 5,199,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -497,000Source | 1,070,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | 1,662,000Source | 2,817,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | -2,979,000Source | -286,000Source | 1,234,000Source | 3,425,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -85,618,000Source | -130,901,000Source | -96,512,000Source | -77,102,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 8,154,000Source | 66,990,000Source | -14,883,000Source | -103,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 326,000Source | — | — |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | 0Source | 0Source | 12,000Source |
| Payments for Repurchase of Common StockUSD | — | — | 0Source | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 238,628,000Source | 20,294,000Source | 88,516,000Source | 117,230,000Source |
| Repayments of Long-term DebtUSD | 0Source | 0Source | 2,064,000Source | 795,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 161,377,000Source | -43,773,000Source | -22,780,000Source | 39,920,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 217,852,000Source | 56,475,000Source | 100,248,000Source | 123,028,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 8,053,000Source | 7,766,000Source | 4,604,000Source | 3,006,000Source |
| Income Taxes Paid, NetUSD | 338,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 213,000Source | -156,000Source | 99,000Source | -105,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 4,298,000Source | 8,204,000Source | 8,687,000Source | 5,199,000Source |
| Amortization of Intangible AssetsUSD | — | 500,000Source | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 253,000,000Source | 102,100,000Source | 114,200,000Source | — |
| DepreciationUSD | 500,000Source | — | — | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | 12,778,000Source | 1,928,000Source | 7,074,000Source | 1,701,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | 0Source | 105,000,000Source | 0Source | 509,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 43,516,000Source | 61,518,000Source | 35,505,000Source | 27,020,000Source |
| GoodwillUSD | 17,351,000Source | 17,351,000Source | 17,351,000Source | 17,351,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 41,000Source | 310,000Source | 78,000Source | 28,000Source |
| InterestExpenseNonoperatingUSD | 8,876,000Source | 8,768,000Source | — | — |
| Investment Income, InterestUSD | 4,576,000Source | 5,769,000Source | 4,582,000Source | 219,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | 13,000Source | -3,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -79,199,000Source | -37,450,000Source | -101,167,000Source | -93,867,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -37,450,000Source | -101,167,000Source | -96,413,000Source |
| Nonoperating Income (Expense)USD | 7,725,000Source | -739,000Source | 6,433,000Source | -6,270,000Source |
| Operating ExpensesUSD | — | — | 107,522,000Source | 87,569,000Source |
| Other Nonoperating Income (Expense)USD | -753,000Source | 332,000Source | 554,000Source | -4,197,000Source |
| Proceeds from Issuance of Common StockUSD | 238,530,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 35,113,000Source | 2,557,000Source | — | 0Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | -86,883,000Source | -36,401,000Source | -107,522,000Source | -87,569,000Source |
| Other Nonoperating Income (Expense)USD | -753,000Source | 332,000Source | 554,000Source | -4,197,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -79,158,000Source | -37,140,000Source | -101,089,000Source | -93,839,000Source |
| Income Tax Expense (Benefit)USD | 41,000Source | 310,000Source | 78,000Source | 28,000Source |
| Net Income (Loss) Attributable to ParentUSD | -79,199,000Source | -37,450,000Source | -101,167,000Source | -93,867,000Source |
| Earnings Per Share, BasicUSD per share | -1.87Source | -0.19Source | -0.57Source | -1.52Source |
| Earnings Per Share, DilutedUSD per share | -1.87Source | -0.19Source | -0.57Source | -1.52Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 42,292,818Source | 201,062,211Source | 177,812,480Source | 63,526,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 42,292,818Source | 201,062,211Source | 177,812,480Source | 63,526,000Source |
| Interest Expense (non-operating)USD | 8,876,000Source | 8,768,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | 500,000Source | — | — |
| Costs and ExpensesUSD | — | 38,958,000Source | — | — |
| General and Administrative ExpenseUSD | 43,516,000Source | 61,518,000Source | 35,505,000Source | 27,020,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -79,409,000Source | -38,846,000Source | -102,126,000Source | -94,742,000Source |
| Interest ExpenseUSD | — | — | 5,777,000Source | 3,993,000Source |
| Investment Income, InterestUSD | 4,576,000Source | 5,769,000Source | 4,582,000Source | 219,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -37,450,000Source | -101,167,000Source | -96,413,000Source |
| Nonoperating Income (Expense)USD | 7,725,000Source | -739,000Source | 6,433,000Source | -6,270,000Source |
| Operating ExpensesUSD | — | — | 107,522,000Source | 87,569,000Source |
| Research and Development ExpenseUSD | 72,723,000Source | 81,643,000Source | 72,017,000Source | 61,058,000Source |
Filing attachments
xforex41formofpre-fundedwa.htm · 8-K · 2025-10-27
EX-4.1 3 xforex41formofpre-fundedwa.htm EX-4.1 Document Exhibit 4.1 X4 PHARMACEUTICALS, INC. [FORM OF] PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [l] (subject to adjustment) Warrant No. PF-2025-[l] Original Issue Date: [l], 2025 X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [l] or its registered assigns (the “Holder”), is entit…
Read attachment ↗ex991_2025916release.htm · 8-K · 2025-09-17
EX-99.1 2 ex991_2025916release.htm EX-99.1 Document Exhibit 99.1 X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M John Volpone appointed Chief Operating Officer, in addition to his current role as President Dr. Adam Craig, Executive Chairman, to have oversight over clinical develop…
Read attachment ↗ex-41formofaugust2025prexf.htm · 8-K · 2025-08-12
EX-4.1 2 ex-41formofaugust2025prexf.htm EX-4.1 Document Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE S…
Read attachment ↗